A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma

被引：0
|
作者：
Patel, S. P. [1 ]
Hodi, F. S. [2 ]
Gabrilovich, D. [3 ]
Chin, M. [4 ]
Gibney, G. [5 ]
Goldsberry, A. [4 ]
Gonzalez, R. [6 ]
Hurt, J. [4 ]
Markowitz, J. [7 ]
Whitman, E. [8 ]
Meyer, C. [4 ]
Salama, A. [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Wistar Inst Anat & Biol, Immunol, 3601 Spruce St, Philadelphia, PA 19104 USA
[4] Reata Pharmaceut, Prod Dev, Irving, TX USA
[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Univ Colorado, Sch Med, Denver, CO USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol, Tampa, FL USA
[8] Atlantic Hlth Syst Canc Care, Morristown, NJ USA
[9] Duke Univ, Sch Med, Durham, NC USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5O_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients
    Leung, Abraham C. F.
    Kummar, Shivaani
    Agarwala, Sanjiv S.
    Nemunaitis, John J.
    Gonzalez, Rene
    Drabick, Joseph J.
    Schmidt, Emmett V.
    Chartash, Elliot
    Xing, Biao
    Currie, Graeme
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
    Bendell, Johanna
    Fuchs, Charles
    Voss, Martin
    Bauer, Todd M.
    Choueiri, Toni K.
    Drilon, Alexander
    Thorn, Katharine
    Wijayawardana, Sameera
    Moser, Brian
    Urunuela, Arantxa
    Wacheck, Volker
    Harding, James J.
    CANCER RESEARCH, 2017, 77
  • [23] Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer.
    Le, Dung T.
    Cruz-Correa, Marcia
    Bajor, David L.
    Garcia-Carbonero, Rocio
    Harris, Marion
    Pazo-Cid, Roberto
    Kindler, Hedy
    Yee, Nelson
    Kamath, Suneel
    Patel, Maulik
    Fang, Hua
    Henner, William
    Hardesty, Patrick
    Blaney, Martha
    McDevitt, Michael
    Golan, Talia
    CANCER RESEARCH, 2022, 82 (12)
  • [24] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    CANCER RESEARCH, 2017, 77
  • [25] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Diab, Sami
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Young, Louise
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176
  • [27] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S16 - S16
  • [28] a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer (vol 26, 32, 2024)
    Shatsky, Rebecca A.
    Batra-Sharma, Hemali
    Helsten, Teresa
    Schwab, Richard B.
    Pittman, Emily I.
    Pu, Minya
    Weihe, Elizabeth
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Molinolo, Alfredo
    Cabrera, Betty
    Breitmeyer, James B.
    Widhopf II, George F.
    Messer, Karen
    Jamieson, Catriona
    Kipps, Thomas J.
    Parker, Barbara A.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [29] The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
    Curti, B.
    Richards, J.
    Faries, M.
    Andtbacka, R. H. I.
    Grose, M.
    Karpathy, R.
    Shafren, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Angevin, Eric
    Hong, David S.
    Rybkin, Igor I.
    Barve, Minal
    Bauer, Todd M.
    Delmonte, Angelo
    Dunbar, Martin
    Motwani, Monica
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Blot, Vincent
    Kelly, Karen
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
12345